Fresh analysis reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop conventional diet and exercise plans.
Research printed in a major medical journal shows that while overweight individuals often shed a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such drugs need to be aware of the risk of quick rebound weight gain when the treatment ends," cautioned expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to original mass in about one and a half years.
Analyzing Treatments
The study, which looked at 37 of studies involving thousands of patients, contrasted the results of these new drugs with older methods.
The team point out that people who lose weight through dieting generally see a less rapid weight regain—approximately 100 grams monthly—once they finish.
Understanding the Quick Regain
Experts propose the mode of action of the drugs is key to understanding the accelerated rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating much more probable."
An Ongoing Condition?
Medical guidelines advise the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts contend that, due to the high risk of weight regain, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who note that the findings "highlight the persistent character of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the medication report a sudden resurgence of hunger.
"It felt as if a switch activating and I was suddenly ravenous," said an individual.
The struggle is exacerbated if patients have not developed sustainable dietary or behavioural changes during treatment.
Significant Interest
Survey data show that millions of people in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is higher among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing lifestyle management.
